Recent analyses on retatrutide, a dual stimulant for GLP-1 and glucose-dependent insulinotropic polypeptide, indicate significant results in managing obesity and type 2 glucose intolerance. Preliminary information from clinical assessments reveal notable diminutions in body bulk and enhanced glucose control. Ongoing research is focused on long-term